BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35780757)

  • 1. Expressional regulation of NKG2DLs is associated with the tumor development and shortened overall survival in lung adenocarcinoma.
    Kucuk B; Cacan E
    Immunobiology; 2022 Jul; 227(4):152239. PubMed ID: 35780757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression profiles of Natural Killer Group 2D Ligands (NGK2DLs) in colorectal carcinoma and changes in response to chemotherapeutic agents.
    Kucuk B; Yilmaz E; Cacan E
    Mol Biol Rep; 2021 May; 48(5):3999-4008. PubMed ID: 34009568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
    Kim Y; Born C; Bléry M; Steinle A
    Front Immunol; 2020; 11():960. PubMed ID: 32582150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology.
    Secchiari F; Nuñez SY; Sierra JM; Ziblat A; Regge MV; Raffo Iraolagoitia XL; Rovegno A; Ameri C; Secin FP; Richards N; Ríos Pita H; Vitagliano G; Rico L; Mieggi M; Frascheri F; Bonanno N; Blas L; Trotta A; Friedrich AD; Fuertes MB; Domaica CI; Zwirner NW
    Oncoimmunology; 2022; 11(1):2104991. PubMed ID: 35936986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
    Salih HR; Antropius H; Gieseke F; Lutz SZ; Kanz L; Rammensee HG; Steinle A
    Blood; 2003 Aug; 102(4):1389-96. PubMed ID: 12714493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing NKG2D ligand-targeting miRNAs enhances natural killer cell-mediated cytotoxicity in breast cancer.
    Shen J; Pan J; Du C; Si W; Yao M; Xu L; Zheng H; Xu M; Chen D; Wang S; Fu P; Fan W
    Cell Death Dis; 2017 Apr; 8(4):e2740. PubMed ID: 28383557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.
    Vulpis E; Loconte L; Cassone C; Antonangeli F; Caracciolo G; Masuelli L; Fazio F; Petrucci MT; Fionda C; Soriani A; Cerboni C; Cippitelli M; Santoni A; Zingoni A
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.
    Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R
    Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
    Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
    Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
    Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
    Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17.
    Ren J; Nie Y; Lv M; Shen S; Tang R; Xu Y; Hou Y; Zhao S; Wang T
    Cell Mol Immunol; 2015 Nov; 12(6):768-76. PubMed ID: 25363527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation-induced matrix metalloproteinases limit natural killer cell-mediated anticancer immunity in NCI-H23 lung cancer cells.
    Heo W; Lee YS; Son CH; Yang K; Park YS; Bae J
    Mol Med Rep; 2015 Mar; 11(3):1800-6. PubMed ID: 25385045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells.
    Morimoto Y; Yamashita N; Daimon T; Hirose H; Yamano S; Haratake N; Ishikawa S; Bhattacharya A; Fushimi A; Ahmad R; Takahashi H; Dashevsky O; Mitsiades C; Kufe D
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36754452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
    Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
    Front Immunol; 2018; 9():1282. PubMed ID: 29963042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
    Giuliani E; Vassena L; Cerboni C; Doria M
    Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility.
    Shiraishi K; Mimura K; Kua LF; Koh V; Siang LK; Nakajima S; Fujii H; Shabbir A; Yong WP; So J; Takenoshita S; Kono K
    J Gastroenterol; 2016 Dec; 51(12):1101-1111. PubMed ID: 27002316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.